Walleye Trading
CRSP icon

Walleye Trading’s CRISPR Therapeutics CRSP Stock Holding History

Walleye Trading’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
18,595
+3,509
+23% +$185K ﹤0.01% 2288
2026
Q1 		$718K Sell
15,086
-2,624
-15% -$138K ﹤0.01% 2353
2025
Q4 		$929K Buy
+17,710
New +$1.06M ﹤0.01% 2425
2025
Q2 		– Sell
-33,453
Closed -$1.29M – 4302
2025
Q1 		$1.14M Buy
+33,453
New +$1.42M ﹤0.01% 1978
2024
Q4 		– Sell
-8,870
Closed -$419K – 4308
2024
Q3 		$417K Buy
8,870
+7,173
+423% +$364K ﹤0.01% 2631
2024
Q2 		$91.7K Sell
1,697
-3,510
-67% -$203K ﹤0.01% 3402
2024
Q1 		$355K Buy
+5,207
New +$373K ﹤0.01% 3051
2022
Q1 		– Sell
-4,793
Closed -$301K – 5408
2021
Q4 		$363K Buy
4,793
+4,711
+5,745% +$412K ﹤0.01% 3266
2021
Q3 		$9K Sell
82
-10,390
-99% -$1.3M ﹤0.01% 5004
2021
Q2 		$1.7M Buy
+10,472
New +$1.27M 0.01% 1632
2020
Q1 		– Sell
-2,718
Closed -$140K – 4053
2019
Q4 		$166K Sell
2,718
-4,197
-61% -$229K ﹤0.01% 3279
2019
Q3 		$283K Buy
+6,915
New +$330K ﹤0.01% 2640
2019
Q1 		– Sell
-20,791
Closed -$719K – 4275
2018
Q4 		$594K Buy
+20,791
New +$723K ﹤0.01% 2305

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Walleye Trading's CRSP Position: Q2 2026 in Review

Walleye Trading increased its CRISPR Therapeutics (CRSP) stake by 23% in Q2 2026, buying an estimated $185K and bringing the position to 18,595 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2288.

Walleye Trading first reported a position in CRSP in Q4 2018 and has held it in 13 quarters since. The position peaked at $1.7M in Q2 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Walleye Trading held 18,595 shares of CRISPR Therapeutics worth $1.01M as of Q2 2026.
  • Walleye Trading bought 3,509 CRISPR Therapeutics shares in Q2 2026, an estimated $185K.
  • CRISPR Therapeutics made up ﹤0.01% of Walleye Trading's portfolio in Q2 2026, its #2288 holding.
  • Walleye Trading first reported a position in CRISPR Therapeutics in Q4 2018 and has held it in 13 quarters since.
  • Walleye Trading's CRISPR Therapeutics position peaked at $1.7M in Q2 2021.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Walleye Trading's 13F filing for Q2 2026, filed 3 Aug 2026.